Ignite Creation Date:
2025-12-25 @ 2:34 AM
Ignite Modification Date:
2026-03-07 @ 9:08 PM
Study NCT ID:
NCT01772134
Status:
COMPLETED
Last Update Posted:
2018-01-29
First Post:
2013-01-17
Is NOT Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
Efficacy and Safety of the Addition of Fluticanse Propionate/Salmeterol (250/50mcg) Twice-daily to 2 Doses of Umeclidinium Bromide (62.5 or 125mcg) Once-daily Over 12 Weeks
Sponsor:
GlaxoSmithKline
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2013-01-01
Start Date Type:
None
Primary Completion Date:
2013-07-01
Primary Completion Date Type:
ACTUAL
Completion Date:
2013-07-22
Completion Date Type:
ACTUAL
First Submit Date:
2013-01-17
First Submit QC Date:
None
Study First Post Date:
2013-01-21
Study First Post Date Type:
ESTIMATED
Results First Submit Date:
2014-03-06
Results First Submit QC Date:
None
Results First Post Date:
2014-04-16
Results First Post Date Type:
ESTIMATED
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2018-01-25
Last Update Post Date:
2018-01-29
Last Update Post Date Type:
ACTUAL